Twitter Hires Health Media Expert
The social media giant has hired Lisa Bookwalter, previous Healthline Media veteran, to oversee its rapidly growing health and wellness department. As the new Director, Twitter Client Services, Health, Bookwalter will be responsible for driving partnerships and revenue growth and opening ad opportunities in the digital space for pharma on Twitter. Bookwalter comments, “Health companies are changing the world; they are at the center of innovation in so many ways, so I’m thrilled to join the team and introduce more health companies to the opportunities they have on the platform.”
Bookwalter will lead Twitter’s year-old health and wellness vertical. Twitter’s Managing Director, Brad Keown, says with Bookwalter’s experience, the social media agency will “be able to offer digital solutions that match the industry’s hunger.”
Jeff Berg Appointed as President of AbelsonTaylor
For the first time in its 38-year history, AbelsonTaylor has appointed a new President,
Jeff Berg, formerly the Executive Vice President and Director of Client Services at the agency. After 17 years with the company and three decades of experience in healthcare, Berg will spearhead future-focused initiatives designed to drive agency growth and expand into new business areas.
As an innovator who combines deep scientific knowledge with remarkable business smarts, Berg has played a key role in expanding AbelsonTaylor’s expertise in technology-driven marketing. “Jeff quickly understands things, whether it’s technical concepts or someone’s emotions, and figures out how to meet objectives, whether it’s long-range brand planning or helping someone advance in his or her career,” Founder Dale Taylor said in a statement. “He moves things forward and that’s a great strength in his new position.”
Luis Vargas, MD joins the Aerie team as Medical Director, Medical Affairs. He will take charge of organizational planning and operational matters at the eye disease company as it works to build its ophthalmology franchise. Most recently, Dr. Vargas was VP of Medical Affairs at ReVision Optics.
The precision genetic medicine company developing gene therapies to restore and preserve hearing, appoints Gregory Robinson, PhD, to the role of Chief Scientific Officer. Dr. Robinson brings more than 20 years of scientific leadership experience, most recently serving as the Chief Scientific Officer at Nightstar Therapeutics. His insight and experience will be valuable in advancing the company’s portfolio of gene therapies for the deaf and hard-of-hearing.
The global pharma giant makes two key additions to its team with Phil Tennant joining as Brand General Manager for new products in the company’s oncology franchise, and Anthony Yanni, MD, who will become Senior Vice President, Patient Centricity.
Tennant will be responsible for setting a unified global brand direction for new oncology products and leading the creation of marketing strategies for these products across priority markets. He most recently served as Head, Hematology Marketing, U.S. Oncology at Bristol-Myers Squibb. Dr. Yanni was most recently Global Head, Patient Insights, Solutions, and Outcomes for Sanofi Medical, where he created one of the first-in-industry processes to integrate the patient and clinician perspective into research portfolio decision-making. He will now lead the development and execution of Astellas’ global patient centricity strategy.
The biotech company focused on developing precision genetic medicines through base editing, hires finance veteran Terry-Ann Burrell as its new Chief Financial Officer. Burrell joins the company from J.P. Morgan, where she was a Managing Director in the healthcare investment banking group, throughout the biotech and pharma industries. She will focus on expanding Beam’s investment in base editing.
Following the departure of Allan Hillgrove, Boehringer appoints Dr. Carine Brouillon to the Board of Managing Directors, effective 2020. For the last year, Dr. Brouillon has been leading the therapeutic areas for prescription medicines at the pharma company. In her new role, she will continue to align the human pharmaceutical business to future needs of patients.
The Ashfield company and the world’s leading rare disease agency, Cambridge BioMarketing, announces the appointment of Ben Beckley as President. Beckley has been part of the executive team at Ashfield since 2018 and previously served as Global Commercial Director of Ashfield Healthcare Communications. He will now oversee agency operations and support the firm’s next chapter of transformation, innovation, and expansion.
Healio Strategic Solutions
The leading medical communications company appoints Chris Rosenberg, a veteran of the organization with more than 20 years of experience, to the role of VP, Client Solutions and Adrienne Stevens, EdD, MEd, MA, a medical strategy and communications expert with more than 15 years of experience, to the newly created position of VP, Scientific Director. Rosenberg will focus on the execution and delivery of the wide variety of educational programs and solutions HSS provides to its clients. Stevens will work closely with the HSS business development team and their clients on developing the most impactful clinical and communications strategies.
The world’s health and wellness information websites leader appoints Laurie Dewan to VP of Consumer Insights. Dewan has a successful history of leading data-driven content strategies across major companies including 20th Century Fox, Warner Bros., and most recently, Electronic Arts (EA). She will be responsible for hiring a team of skilled researchers to help Healthline better understand its users in order to create essential content and tools that help people live healthier lives.
A machine-learning driven drug discovery and development company, insitro, announces Mary M. Rozenman, PhD, as its new Chief Financial Officer and Chief Business Officer. Dr. Rozenman brings more than 15 years of scientific expertise and company-building experience in the biotechnology industry. The drug development veteran will help insitro progress towards its vision of leveraging machine learning and novel data production technologies to more effectively bring medicines to patients in need.
Levi Garraway, Eli Lilly’s recent SVP of Oncology Research & Development and Head of Lilly Research Laboratories Novel Target Research, takes over as Chief Medical Officer and Head of Global Product Development at Roche. He will succeed Sandra Horning, who is retiring after 10 successful years as CMO.